Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis

Vaccine

Volumn 35, Issue 4, 2017, Pages 513-520

  Domnich, Alexander ^a   Arata, Lucia ^a   Amicizia, Daniela ^a   Puig Barberà, Joan ^b   Gasparini, Roberto ^a   Panatto, Donatella ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Area of Vaccines Research   (Spain)

Author keywords

Elderly; Influenza vaccine; Influenza vaccine effectiveness; Meta analysis; MF59 adjuvanted vaccine

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; MF59 OIL EMULSION; POLYSORBATE; SQUALENE;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; FLU LIKE SYNDROME; HOSPITALIZATION; HUMAN; INFLUENZA VACCINATION; META ANALYSIS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; SYSTEMATIC REVIEW; TREATMENT OUTCOME; AGED; IMMUNOLOGY; INFLUENZA; OBSERVATIONAL STUDY; VERY ELDERLY;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; OBSERVATIONAL STUDIES AS TOPIC; POLYSORBATES; SQUALENE; TREATMENT OUTCOME; VACCINES, INACTIVATED;

EID: 85009260860     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.12.011     Document Type: Review

References (44)

1. [1] Simonsen, L., Taylor, R.J., Viboud, C., Miller, M.A., Jackson, L.A., Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 7 (2007), 658–666, 10.1016/S1473-3099(07)70236-0.
2. [2] World Health Organization (WHO), Vaccines against influenza WHO position paper – November 2012. Wkly Epidemiol Rec 87 (2012), 461–476.
3. [3] Gasparini, R., Lucioni, C., Lai, P., Maggioni, P., Sticchi, L., Durando, P., et al. Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria. Vaccine 20:Suppl 5 (2002), B50–B54.
4. [4] Official Journal of the European Union. Council recommendation of 22 December 2009 on seasonal influenza vaccination. < http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:348:0071:0072:EN:PDF>.
5. [5] Rümke, H.C., Richardus, J.H., Rombo, L., Pauksens, K., Plaßmann, G., Durand, C., et al. Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial. BMC Infect Dis, 13, 2013, 348, 10.1186/1471-2334-13-348.
6. [6] O'Hagan, D.T., Tsai, T., Reed, S., Emulsion-based adjuvants for improved influenza vaccines. Del Giudice, G., Rappuoli, R., (eds.) Influenza vaccines for the future, 2nd ed., 2011, Springer, 327–357.
7. [7] Banzhoff, A., Pellegrini, M., Del Giudice, G., Fragapane, E., Groth, N., Podda, A., MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respir Viruses 2 (2008), 243–249, 10.1111/j.1750-2659.2008.00059.x.
8. [8] Tsai, T.F., Fluad®-MF59®-adjuvanted influenza vaccine in older adults. Infect Chemother 45 (2013), 159–174, 10.3947/ic.2013.45.2.159.
9. [9] Podda, A., The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19 (2001), 2673–2680.
10. [10] Pellegrini, M., Nicolay, U., Lindert, K., Groth, N., Della Cioppa, G., MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 27 (2009), 6959–6965, 10.1016/j.vaccine.2009.08.101.
11. [11] Camilloni, B., Basileo, M., Valente, S., Nunzi, E., Iorio, A.M., Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: a literature review. Hum Vaccin Immunother 11 (2015), 553–563, 10.1080/21645515.2015.1011562.
12. [12] Weinberg, G.A., Szilagyi, P.G., Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J Infect Dis 201 (2010), 1607–1610, 10.1086/652404.
13. [13] Stroup, D.F., Berlin, J.A., Morton, S.C., Olkin, I., Williamson, G.D., Rennie, D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283 (2000), 2008–2012, 10.1001/jama.283.15.200.
14. [14] World health organization (WHO). Definition of an older or elderly person. < http://www.who.int/healthinfo/survey/ageingdefnolder/en/>.
15. [15] Osterholm, M.T., Kelley, N.S., Sommer, A., Belongia, E.A., Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12 (2012), 36–44, 10.1016/S1473-3099(11)70295-X.
16. [16] Vu, T., Farish, S., Jenkins, M., Kelly, H., A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 20 (2002), 1831–1836.
17. [17] Jefferson, T., Di Pietrantonj, C., Al-Ansary, L.A., Ferroni, E., Thorning, S., Thomas, R.E., Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev(2), 2010, CD004876, 10.1002/14651858.CD004876.pub.
18. [18] Frey, S.E., Reyes, M.R., Reynales, H., Bermal, N.N., Nicolay, U., Narasimhan, V., et al. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 32 (2014), 5027–5034, 10.1016/j.vaccine.2014.07.013.
19. [19] Minutello, M., Senatore, F., Cecchinelli, G., Bianchi, M., Andreani, T., Podda, A., et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 17 (1999), 99–104.
20. [20] An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI). Literature review on pediatric Fluad® influenza vaccine use in children 6-72 months of age. < http://www.phac-aspc.gc.ca/naci-ccni/assets/pdf/pediatric-pediatrique-fluad-eng.pdf>.
21. [21] Wells GA, Shea B, O'Connell D, Peterson JEA, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. < http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>.
22. [22] Beck, C.R., McKenzie, B.C., Hashim, A.B., Harris, R.C., Zanuzdana, A., Agboado, G., et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective. PLoS ONE, 6, 2011, e29249, 10.1371/journal.pone.0029249.
23. [23] Barendregt JJ, Suhail AD. MetaXL User Guide. < http://www.epigear.com/index_files/MetaXL%20User%20Guide.pdf>.
24. [24] Puig-Barberà, J., Diez-Domingo, J., Pérez Hoyos, S., Belenguer Varea, A., González Vidal, D., Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age. Vaccine 23 (2004), 283–289, 10.1016/j.vaccine.2004.07.01.
25. [25] Iob, A., Brianti, G., Zamparo, E., Gallo, T., Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect 133 (2005), 687–693.
26. [26] Puig-Barberà, J., Díez-Domingo, J., Varea, A.B., Chavarri, G.S., Rodrigo, J.A., Hoyos, S.P., et al. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine 25 (2007), 7313–7321, 10.1016/j.vaccine.2007.08.039.
27. [27] Puig-Barberà, J., Díez-Domingo, J., Arnedo-Pena, A., Ruiz-García, M., Pérez-Vilar, S., Micó-Esparza, J.L., et al. Effectiveness of the 2010–2011 seasonal influenza vaccine in preventing confirmed influenza hospitalizations in adults: a case-case comparison, case-control study. Vaccine 30 (2012), 5714–5720, 10.1016/j.vaccine.2012.07.006.
28. [28] Mannino, S., Villa, M., Apolone, G., Weiss, N.S., Groth, N., Aquino, I., et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 176 (2012), 527–533, 10.1093/aje/kws313.
29. [29] Van Buynder, P.G., Konrad, S., Van Buynder, J.L., Brodkin, E., Krajden, M., Ramler, G., et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine 31 (2013), 6122–6128, 10.1016/j.vaccine.2013.07.059.
30. [30] Gasparini, R., Amicizia, D., Lai, P.L., Rossi, S., Panatto, D., Effectiveness of adjuvanted seasonal influenza vaccines (Inflexal V ® and Fluad ®) in preventing hospitalization for influenza and pneumonia in the elderly: a matched case-control study. Hum Vaccin Immunother 9 (2013), 144–152, 10.4161/hv.22231.
31. [31] Puig-Barberà, J., Natividad-Sancho, A., Calabuig-Pérez, J., Lluch-Rodrigo, J.A., Pastor-Villalba, E., Martínez-Úbeda, S., et al. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system. Vaccine 31 (2013), 3995–4002, 10.1016/j.vaccine.2013.05.070.
32. [32] Spadea, A., Unim, B., Colamesta, V., Meneghini, A., D'Amici, A.M., Giudiceandrea, B., et al. Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study. Vaccine 32 (2014), 5290–5294, 10.1016/j.vaccine.2014.07.077.
33. [33] Manzoli, L., Ioannidis, J.P., Flacco, M.E., De Vito, C., Villari, P., Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses. Hum Vaccin Immunother 8 (2012), 851–862, 10.4161/hv.19917.
34. [34] Gross, P.A., Hermogenes, A.W., Sacks, H.S., Lau, J., Levandowski, R.A., The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 123 (1995), 518–527.
35. [35] Jefferson, T., Rivetti, D., Rivetti, A., Rudin, M., Di Pietrantonj, C., Demicheli, V., Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 366 (2005), 1165–1174, 10.1016/S0140-6736(05)67339-4.
36. [36] Baxter, D., Evaluating the case for trivalent or quadrivalent influenza vaccines. Hum Vaccin Immunother 12 (2016), 2712–2717, 10.1080/21645515.2015.1091130.
37. [37] Moa, A.M., Chughtai, A.A., Muscatello, D.J., Turner, R.M., MacIntyre, C.R., Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: a systematic review and meta-analysis of randomised controlled trials. Vaccine 34 (2016), 4092–4102, 10.1016/j.vaccine.2016.06.064.
38. [38] Ambrose, C.S., Levin, M.J., The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 8 (2012), 81–88, 10.4161/hv.8.1.17623.
39. [39] Reed, C., Meltzer, M.I., Finelli, L., Fiore, A., Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 30 (2012), 1993–1998, 10.1016/j.vaccine.2011.12.098.
40. [40] Beyer WE, Boulfich M, Osterhaus AD. QIV versus TIV: evidence-based impact of lineage mismatch on influenza B vaccine efficacy. An umbrella meta-analysis of published literature. Presented at: The fifth international conference and exhibition on influenza vaccines for the world; 6–9 October 2015, Albufeira, Algrave, Portugal.
41. [41] Landis, J.R., Koch, G.G., The measurement of observer agreement for categorical data. Biometrics 33 (1977), 159–174, 10.2307/2529310.
42. [42] Hartling, L., Milne, A., Hamm, M.P., Vandermeer, B., Ansari, M., Tsertsvadze, A., et al. Testing the Newcastle Ottawa Scale showed low reliability between individual reviewers. J Clin Epidemiol 66 (2013), 982–993, 10.1016/j.jclinepi.2013.03.003.
43. [43] Lo, C.K., Mertz, D., Loeb, M., Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. BMC Med Res Methodol, 14, 2014, 45, 10.1186/1471-2288-14-45.
44. [44] Chan, T.C., Fan-Ngai Hung, I., Ka-Hay Luk, J., Chu, L.W., Hon-Wai Chan, F., Effectiveness of influenza vaccination in institutionalized older adults: a systematic review. J Am Med Dir Assoc, 15, 2014, 10.1016/j.jamda.2013.10.00 226.e1-6.